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Background: Since their introduction into clinical trials in the United States, endovascular aortic grafts have shown
various types of problems. Although details of design and construction vary between different endovascular grafts and
failure modes have had a variety of causes and clinical effects, the inability of preclinical testing to predict these failures
remains common to all endovascular grafts. The need to improve preclinical testing in an attempt to reduce clinical device
failures resulted in a Food and Drug Administration–sponsored workshop on endovascular graft preclinical testing held
in Rockville, Md, from July 31 to August 1, 2001.
Format: The workshop was not designed as a consensus conference. Instead, it provided a forum for bringing stakeholders
together to define problems and identify areas of agreement and disagreement. The workshop had 34 invited participants
who represented device manufacturers, the medical community, the Food and Drug Administration, and testing facilities,
and international attendance was more than 120 people.
Outcome: Discussion centered on: 1, defining the physiologic, anatomic, and morphologic characteristics of abdominal
aortic aneurysms before and after endovascular graft treatment; 2, identifying the types of failures that have been
observed clinically; and 3, determining which characteristics should be considered during preclinical modeling to better
predict clinical performance. Attendees agreed to the need to better define and address anatomic characteristics and
changes in the aneurysm after endograft treatment to optimize preclinical testing. Much discussion and little agreement
occurred on the importance of flow-related forces on graft performance or the need or ability to define and model
physiologic compliance during durability testing. The discussion and conclusions are summarized in this paper and are
provided in detail at: http://www.fda.gov/cdrh/meetings/073101workshop.html.
Conclusion: The workshop raised awareness of significant performance issues and the challenges of modeling the
extremely variable and relatively undefined environment of abdominal aortic aneurysms. Through the interactive format
of the workshop, participants identified areas of preclinical testing, device design, and aspects of the simulated
environment that need further consideration. (J Vasc Surg 2002;35:1022-8.)
As endovascular graft devices came into broad investi-
gational use, unanticipated changes in the endovascular
graft and in the arterial segment excluded by the graft were
observed. Many successfully excluded abdominal aortic
aneurysms (AAAs) were shrinking in size, sometimes result-
ing in changes in the alignment, angulation, and luminal
shape of the endovascular graft.1-4 Soon, clinical reports
began to appear describing adverse events, such as endo-
vascular graft migration, failure to seal or completely ex-
clude the aneurysm, and loss of integrity either in the form
of separation of modular components or in fabric perfora-
tion.5,6 Clinicians, government regulators, and the medical
device industry recognized that preclinical testing had not
been successful at predicting the various failure modes seen
in the clinic.7,8 This widespread recognition prompted a
workshop on endovascular graft preclinical testing spon-
sored by the US Food and Drug Administration on July 31
and August 1, 2001, which had international attendance of
more than 120 people, including 34 invited participants.
This workshop was not intended to be a consensus con-
ference, rather, a problem-definition workshop. Changing the
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specific requirements for preclinical testing, particularly from a
regulatory standpoint, would require an extremely high level
of agreement. Such agreement is not plausible at this time
because the forces acting on endovascular grafts have not yet
been completely identified and defined. Instead, dialogue
concerning improving preclinical testing was initiated among
the wide range of disciplines encompassing the diverse
community involved in the design, development, testing,
manufacture, use, and regulation of endovascular grafts.
Complete documentation of the workshop proceedings,
including transcripts and slides of the presentations, work
completed in preparation for the meeting, and comments
made during the meeting can be found at http://www.
fda.gov/cdrh/meetings/073101workshop.html. This ar-
ticle, authored by the steering committee for the workshop,
represents a synopsis of comments obtained both in ad-
vance of the meeting and at the workshop.
WORKSHOP FORMAT
The Food and Drug Administration Workshop on
PreClinical Testing of Endovascular Grafts was organized
by a steering committee comprised of volunteers from the
vascular prostheses working group of the International
Organization of Standardization (ISO) and Hugh G.
Beebe, MD, who was invited to join the committee as a
representative of the medical community. The ISO work-
ing group is responsible for developing international stan-
dards for testing and evaluation of endovascular grafts and
is currently supporting the development of methods for
preclinical testing of these devices. This working group will
have the opportunity to incorporate feedback from the
workshop into these test methods.
Stakeholders from research, testing, manufacturing,
medical, and regulatory communities were invited to par-
ticipate in the workshop. In preparation, these participants
were asked to respond to a detailed work assignment.
Completed assignments were compiled into a document
that formed the basis for discussion during the meeting.
The assignment involved defining physiologic, anatomic,
and morphologic characteristics of AAAs before and after
endovascular graft treatment; identifying the types of fail-
ures that have been observed clinically; and determining
which characteristics should be considered during preclin-
ical modeling to better predict clinical performance. Al-
though preclinical in vivo testing was briefly discussed and
included in the work assignment, the focus of the workshop
was in vitro evaluation of endovascular grafts.
Although references could be provided in the work
assignment, the knowledge base was primarily the personal
experience of the attendees. Much information regarding
design and testing of endovascular grafts, and failure anal-
ysis, are not in the literature and were the focus of the
discussion.
Both the work assignment and the discussion centered
on a series of six questions, most of which required answers
in a tabular format. Both days of the workshop included
keynote speakers followed by working roundtable discus-
sions by invited participants regarding these questions. In
addition, opportunity for audience comment existed
throughout the workshop.
WORKSHOP OUTCOMES
Not all information in the compiled work assignment
was discussed during the workshop because of time con-
straints. However, the most critical topics were discussed in
detail. The following summary of results describes the
information captured in the completed tables and reflects
both the information provided in preparation for the work-
shop and the discussions that took place during the work-
shop. This report focuses primarily on areas of agreement
and disagreement relating to physiology, morphology, de-
vice testing, and performance.
Session 1: abdominal aortic aneurysm environment
before treatment
The goals of the first session of the workshop were to
achieve a common understanding of the AAA environment
and to identify limitations of our understanding of this
environment. Table I lists 17 of the anatomic, morpho-
logic, and physiologic characteristics of a diseased aorta
where an endovascular graft could be placed for treatment
of AAA. These characteristics included aneurysm morphol-
ogy, neck characteristics, hemodynamics, and vessel wall
properties. The goal was to identify characteristics affecting
the function or performance of an endovascular graft, iden-
tify the range of the values, rate the importance of the
characteristics, and provide comments and references. Al-
though the discussion covered patient selection, device
design, and in vitro testing characteristics, only the latter
two were the focus of the workshop.
Table I. AAA morphologic and physiologic
characteristics before implant
Aneurysm characteristics
Branch vessels
Iliac involvement
Multiple lesions
Shape
Size
Tortuosity/angulation
Neck characteristics
Angles
Lengths
Shapes
Hemodynamic related characteristics
Blood flow pathway (eg, presence of channels, branches, and
anatomic pathway)
Blood flow rate
Pulse pressure (systolic/diastolic)
Temperature
Vessel wall characteristics
Atheromatous material
Compliance/elasticity (axial and circumferential)
Degree of calcification
Presence of thrombus
For each characteristic, the following points were discussed: 1, range of
probable values; 2, criticality (rated 1 to 5, with 5 as mostimportant); 3,
comments; and 4, references.
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During this session, clear agreement was seen on the
following points, listed in ranked order of considered im-
portance:
1. Neck characteristics significantly affect endovascular
graft performance.
2. Worst case conditions for evaluation of design attributes
need to be determined for each endovascular graft de-
sign.
3. Critical parameters may differ between devices, and
these parameters should be accounted for during pre-
clinical testing.
4. Tortuosity or angulation of the aorta and its branches,
size and shape of the aneurysm, degree of calcification,
and presence of thrombus or atheromatous material are
of fairly high importance in graft performance.
5. An empty aneurysm with no patent branch vessels
would result in the least support to the endovascular
graft and the largest pressure gradient across the graft
wall, hence, it is the best model to use during testing.
The following points reflect areas that need additional
consideration: 1, how to define, measure in vivo, describe,
or quantify characteristics identified previously; 2, how to
appropriately model the characteristics in preclinical test-
ing, given the extreme diversity of the parameters and
interrelationship between parameters, and 3, how to bal-
ance between the “ideal” and what is practical. For exam-
ple, that it might be appropriate to develop a series of
“standard tortuosity” models for preclinical testing on the
basis of clinical documentation was suggested. Devices
then could be tested with these models as part of their
durability evaluations.
No agreement could be reached on the following
points:
1. The presence and relevance of the compliance of the
vessel wall after endovascular graft placement. Signifi-
cant discussion and little consensus existed on: a, pres-
ence or absence of compliance in the diseased aorta; b,
presence or absence of compliance in the aorta in com-
bination with the endovascular graft; c, relevance of
aortic compliance on durability of the implant; and d,
the need to measure compliance or to attempt to simu-
late physiologic compliance in device durability testing.
The opinions on the criticality of this attribute ranged
from it being not relevant to it being critically impor-
tant.
2. The importance of blood flow induced forces on the
endovascular device. The discussion on flow rate re-
vealed divergent points of view ranging from it being
critical to it not being important. Those who were
unsure of the importance expressed concern that be-
cause flow rate is not known, its effects are not known.
The option of evaluating devices over a range of flow
rates was considered. Those who thought forces gener-
ated by flow to be important noted that the forces on the
device depend on the blood flow path (tortuosity) and
flow rate. Several participants agreed that analytic anal-
yses indicate the forces applied to the device as a result of
hemodynamics are relatively insignificant as compared
with effects of pressure, especially when considering
effects of load sharing of longitudinal forces with the
intact aorta and iliac anatomy.
3. Given the diverse clinical situations in endovascular graft
use, defining device performance within appropriate
anatomic conditions is important. Disagreement was
seen, however, as to the extent a device should be
evaluated. Participants varied in opinion as to whether a
device should be tested for all potential anatomic con-
figurations or only for those types of anatomy clearly
indicated in the device labeling. This discussion reem-
phasized the point that ideally a balance should exist
between the robustness of in vitro evaluation and clini-
cal use of the device.
Session 2: abdominal aortic aneurysm environment
after treatment
The goals of the second session of the workshop were
similar to the first, except that they focused on defining the
environment after treatment with an endovascular graft.
Table II lists 21 aneurysm, neck, hemodynamic, and vessel
wall characteristics. Some of these characteristics are the
same as those in Table I, with additional characteristics
related to a treated aneurysm.
During this session, clear agreement was seen on the
following points, listed in ranked order of considered im-
portance:
Table II. AAA morphologic and physiologic
characteristics after implant
Aneurysm characteristics
Endoleak
Type I
Type II
Type III
Type IV
Longitudinal shrinkage
Pressure inside aneurysm
Shape
Size
Tortuosity/angulation
Volume
Neck characteristics
Angles
Lengths
Shape
Size
Hemodynamic related characteristics
Blood flow pathway
Blood flow rate
Corrosive environment
Impact forces
Kinetic (inertial) forces
Shear forces
Vessel wall characteristics
Compliance/elasticity (axial and circumferential)
For each characteristic, the following points were discussed: 1, range of
probable values; 2, criticality (rated 1 to 5, with 5 as mostimportant); 3,
comments; and 4, references.
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1. Changes in neck characteristics after implant are criti-
cally important to consider in conducting preclinical
testing.
2. Testing should be tailored to the device design (eg,
balloon-expandable versus self-expanding, or more or
less radial force). Various device designs will accommo-
date changes in neck characteristics differently and
therefore should be considered in the test model and
testing conditions.
3. The ability of a device to accommodate changes in
volume, shape, and size of the aneurysm is important to
consider.
4. Corrosion of the metallic component as a result of the
chemical environment and also the interaction of dis-
similar metals should be considered during preclinical
testing. This would include different metals used in the
manufacture of one device and the combination of any
devices that are intended to be used together. For
example, if a manufacturer intends for bare stents to be
used for the treatment of reduced flow or endoleaks, the
corrosion potential introduced by the interaction of the
endovascular graft and the bare stent should be evalu-
ated if the bare stent and endovascular graft stent are
made of different metallic materials.
5. Correct processing of the stent or attachment system
fabrication is critical in minimizing the potential for
corrosion.
6. Evaluation of the corrosion potential should include
comparison with known materials.
7. Although all types of endoleaks and sac pressurization
were given fairly high ranks of criticality, generally these
characteristics were considered important to take into
account during the design of the device, rather than
during its preclinical testing.
The following points reflect areas that need additional
consideration: 1, how to incorporate changes in neck char-
acteristics in vitro; 2, whether testing of the endovascular
graft’s response to changes in the aneurysm (eg, shape,
diameter, volume) would be possible or is necessary dy-
namically or only in extreme conditions.
No agreement could be reached on the following
points: 1, the amount and significance of the compliance of
the aorta and its affect on device integrity; 2, the signifi-
cance of forces other than those generated by pressure; and
3, longitudinal shrinkage of the aneurysm has often been
cited as the cause of endovascular graft failure,1,2 however
consensus was not reached on whether longitudinal shrink-
age occurs and if so, whether it is related to device failure.
Session 3: clinical failures
The goal of this session was to list failures of endovas-
cular grafts that have been observed clinically, focusing on
implant failures and excluding delivery failures, delivery
system failures, and failures related to patient selection.
Table III of the work assignment listed 15 potential failure
modes, and respondents identified another 15 failure
modes, some of which were redundant or out of the scope
of the assignment (ie, delivery failures or patient-selection
failures). The table required respondents to identify possi-
ble causal factors and the degree to which the failure could
be evaluated preclinically. For each failure mode, respon-
dents rated the criticality and provided comments.
During this session, clear agreement was seen on the
following points, listed in ranked order of considered im-
portance:
1. Most failure modes are highly critical.
2. Failure modes that are slightly less critical included type
II endoleak, suture breaks not resulting in modular or
seam separation, and twisting of graft limbs.
3. Type II endoleak and endotension are the only failure
modes that could not be adequately reproduced in a
preclinical test.
4. With some failure modes, a definitive relationship be-
tween clinical cause of the failure mode and whether it
could be reasonably simulated in a preclinical test did
not seem necessary. For example, most respondents
believed that kinking of graft limbs was probably caused
by tortuous anatomy, disease progression, and remod-
eling. Nevertheless, agreement existed that simulation
of clinical conditions when characterizing the kink resis-
tance of graft limbs may not be necessary.
5. When considering type IV endoleak, a distinction be-
tween graft porosity (blush) and holes inherent in the
graft design (eg, suture holes) is needed.
The following points reflect areas that need additional
consideration:
1. Whether test methods could be defined that would
simulate accelerated wear to evaluate the potential for
graft wear holes.
2. What the best method is to create kinking of graft limbs
on the bench, taking into consideration whether kink-
ing characteristics change over time and whether a good
definition of kinking exists.
Table III. Failure modes
Endoleak
Type I
Type II
Type III
Type IV
Endotension
Graft wear holes
Kinking of graft limbs
Loss of complete apposition to vessel wall
Metallic component fracture
Migration
Separation of modular components
Suture breaks causing component separation
Sutured-fabric seam failure
Suture breaks: other
Twisting of graft limbs
For each failure mode, the following points were discussed: 1, whether
failure could be evaluated through preclinical testing; 2, primary causal
factors; 3, criticality (rated 1 to 5, with 5 as mostimportant); and 4,
comments.
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3. Clinical relevance of suture breaks might depend on the
primary function of the suture. The concept of simulat-
ing the failure mode in test samples before conducting
various tests was considered.
No agreement could be reached on the clinical rele-
vance of some of the failure modes, particularly the less
critical ones.
Session 4: preclinical tests
The goal of this session was to establish a common
understanding of current preclinical testing and to list
parameters not adequately considered in the individual test
methods. Table IV lists the 30 preclinical tests identified in
the technical specification “ISO/TS 15539:2000—Car-
diovascular implants-Endovascular prostheses”9 that are
applicable to the implanted component of an endovascular
graft system. For each test, participants were asked to
identify the relationship between the test method and
failure modes listed in Table III. The intent of this assign-
ment was to identify tests that should give the most infor-
mation regarding the failure modes. Finally, participants
were asked to identify information that could improve
either test design or the interpretation of test results.
Most of the discussion during the workshop focused on
durability and stress analysis because these were identified
as the most critical areas needing improvement.
During this session, clear agreement was seen on the
following points:
1. Stress analysis and durability are the two critical areas
needing improvement.
2. Duplication of diametric excursions of the endovascular
graft seen in vivo during durability testing is necessary.
3. The following conditions should be considered in de-
veloping preclinical testing: peripheral resistance; longi-
tudinal (axial) and torsional loading; curvature, tortuos-
ity, and angulation of vessels; and changes in neck angle,
shape, and length.
4. Handling, loading of the delivery catheter, and the
condition of test samples should be considered and
addressed when developing test methods.
5. Other factors that should be evaluated in preclinical
testing include failure at the point of attachment, failure
at transition zones (ie, from the necks of the aneurysm
to the aneurysm sac), potential for fractures at the level
of the neck, and potential effects of secondary proce-
dures (eg, ballooning) on device integrity.
6. Testing may not simulate the physiologic situation.
7. Preclinical testing is useful in screening out poor de-
signs.
8. Tests may possibly be made more realistic with actual
patient images to get ranges of anatomic values. How-
ever, current clinical measurement methods need im-
provement before they can be reliably used to form the
basis of preclinical in vitro testing.
9. The need for uniform testing for comparison purposes
was considered. The consensus was that some tests
would be common to all devices whereas others would
need to be designed specifically to evaluate a particular
failure mode or design characteristic for specific device
designs. In addition, conducting separate tests to eval-
uate different design attributes (ie, different compo-
nents and their interactions) may be necessary. Al-
though testing of all designs in one test model, or a set
of test models, simulating in vivo conditions, would be
ideal, the discussants acknowledged that the technology
is not available to accomplish this objective.
The following point reflects areas that need additional
consideration: how to incorporate the recognized impor-
tant factors, listed previously, into preclinical testing.
No agreement could be reached on the following
point: discussions regarding the importance of vessel wall
compliance continued during this session.
Session 5: discussion on limitations of testing
The goals of this session were to: 1, list potential
reasons that preclinical testing identified in session 4 did
not adequately simulate observed clinical failures; 2, iden-
tify unresolved issues; and 3, suggest new test concepts on
the basis of previous discussions. Session 5 included discus-
sion of questions 5 and 6 of the work assignment.
Question 5 of the work assignment was: please discuss
why the tests may not have adequately simulated the ob-
served clinical failures and provide any additional com-
Table IV. Preclinical tests from ISO technical
specification 15539
Burst/circumferential stress
Conformity to vessel wall
Corrosion
Crush resistance
Device diameter to balloon inflation pressure
Device length to diameter relationship
Dimensional verification
Factory anastomotic strength
Fatigue and durability
Durability testing
Finite element analysis
Flex/kink
Integral water permeability
Local compression
Longitudinal tensile strength
Migration resistance
Magnetic resonance imaging compatibility
Porosity
Preclinical in vivo (animal) studies
Pull test for modular components
Radial outward force (hoop strength)
Recoil
Simulated use models
Stent-free surface area
Strength of stent attachment system to graft bond
Stress/strain analysis
Visibility
Visual inspection
Water entry pressure
Water permeability
Description of each test was provided, and the following points were
discussed: 1, which failure modes, listed in Table III, should be evaluated
with test; and 2, information needed to optimize test from Tables I and II.
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ments. This question was intended to determine which
aspects of in vitro modeling are done well and which are
not. Another goal of this section was to develop a list of
limitations in simulating anatomy and physiology. Agree-
ment was seen on the following points with respect to
question 5:
1. In vitro modeling was believed to be adequate for
simulating the following: vessel diameters, flow rates
and pressures, kink angles, crush forces, deployment
accuracy and deployment forces, geometries for static
testing, and potential for endoleaks.
2. Current testing inadequately models the following:
characteristics such as anatomic changes in the aorta
over time, vessel tortuosity, vessel wall characteristics,
wear and fatigue dynamics on components suspended in
the aneurysm sac, pulsatility, and others.
3. Most tests, including finite element analysis and tests
designed to model the in vivo condition, have not been
able to account for the multitude of changing variables
that affect the long-term results of endovascular grafts.
4. Consideration of the delivery system as an integral part
of the endovascular graft is important to consider be-
cause delivery affects long-term performance of the im-
plant.
5. Evaluation of areas of flexure, overlap, transition zones,
and the interaction between modular components is
needed.
6. Consideration of the nonconcentric loading of attach-
ment systems in the design and evaluation of delivery
systems should exist.
7. Significant discrepancies exist between parameters used
in the in vitro test models and various parameters ob-
served in treated and untreated AAA disease.
Question 6 of the work assignment was: please list any
unresolved issues and identify possible test concepts that
may need to be developed to address the remaining critical
parameters/failure modes. In response to this question, a
total of 29 unresolved issues were identified. These were
broadly categorized in common themes, such as tests relat-
ing to metal fractures, fabric erosion, wear holes, separation
of modular components, aneurysm remodeling effects, and
others. Agreement was seen on the following points with
respect to question 6:
1. Many of the test concepts discussed in this session were
consistent with the comments from previous sessions of
the workshop, including the need to: a, model arterial
curvature; b, evaluate the interaction between modular
components; c, focus on transition zones; d, determine
flexure site forces and effects; and e, evaluate endovas-
cular graft tolerance to balloon dilatation during rein-
tervention procedures.
2. Simulation of movement between components of the
endovascular graft (eg, between the covering and stent
or attachment system) is needed.
3. Evaluation of the effects of system integrity (eg, frac-
tures, suture breaks, wear holes) on device function and
performance requirements are needed.
DISCUSSION
The purpose of endovascular grafting is to minimize or
eliminate the risk of aneurysm rupture with minimally
invasive techniques.10 The purpose of in vitro preclinical
testing is to evaluate mechanical attributes of device design
and the potential for success or failure of the therapy.8
Preclinical testing also serves to provide documented evi-
dence of the minimization of the risk of failure in clinical
use. This evaluation includes assessment of device integrity,
attachment, exclusion of the aneurysm (seal), and the abil-
ity to maintain a patent lumen. During the workshop, the
physical, mechanical, and anatomic conditions that may
affect the interaction between the device and vessel were
identified. Conditions that have not been fully incorpo-
rated into in vitro testing may be categorized according to
their potential effect on clinical performance of the endo-
vascular graft, that is, by the effect on integrity, patency,
attachment, or exclusion/seal.
Several conditions that have not been adequately mod-
eled in vitro can impact a number or all of the design and
performance attributes. Most notably, changes in the an-
eurysm may adversely contribute to all aspects of device
performance. However, modeling the changes in vitro is
not readily done because of the diversity and unpredictable
nature of these changes. Clearly, no single test can be
developed to evaluate all factors that could be affected by
the changes. Multiple tests or multiple test conditions for a
specific test may be needed to show the ability of a specific
device to maintain adequate performance in various im-
plant conditions. In addition, consideration of the variable
implant environment is critical when designing the device.
Similarly, incorporating realistic anatomic characteristics,
including the proximal attachment zone, in test models is
difficult. These characteristics significantly affect all aspects
of device performance and should be addressed during
design and testing.
Other conditions that may greatly impact graft perfor-
mance have more specific effects. Graft kinking or twisting
most likely would impact patency and possibly device in-
tegrity.11,12 Corrosion, tortuosity, changes in the aneu-
rysm, compliance, transition zones, overlap, and secondary
interventions may all affect device integrity.3,13,14 The ves-
sel wall frictional environment and angulation of, and
changes in, the aneurysm and neck may affect attach-
ment.5,15 Exclusion of the aneurysm (seal) is most likely
impacted by vessel wall characteristics (eg, angulation, cal-
cification, and frictional environment) and graft permeabil-
ity and holes in the graft wall.
Overall awareness of these significant performance is-
sues and challenges was realized by the endovascular graft-
ing community during the workshop. The participants
appreciated the importance of design-specific tests and
design-specific performance. The desire to determine the
forces on all parts of the device, including the direction,
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magnitude, and distribution of these forces, as a function of
the anatomy, physiology, and morphology also was appre-
ciated. In vitro testing may be limited, however, by an
overemphasis on attempting to literally simulate the clinical
environment. The anatomic and physiologic environment
determines the forces affecting endovascular grafts. In vitro
testing should be designed to subject the endovascular graft
to forces that meet or exceed those encountered clinically.
What is essential and lacking is knowledge of relevant
stress-strain characteristics.
This workshop initiated problem definition on a broad
level. Because of time constraints, some of the work done in
preparation was not fully explored. The focus of future
workshops could include durability testing, definition of
anatomic characteristics and recommendations for incor-
porating these characteristics appropriately during in vitro
testing, and definition of stresses placed on endovascular
grafts as a result of several factors, including bending,
pulsatile pressure, and vessel compliance. The information
already compiled may form the basis for ongoing discussion
and future workshops regarding these topics.
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